Seminar IKF Friday January 23rd 11-11.45 with Madiha Derouazi A novel cell penetrating peptide as vector for therapeutic vaccine
The Section for Cellular Therapy has the pleasure to invite Madiha Derouazi (CEO, AMAL Therapeutics, Geneva) to hold a seminar entitled:
“A novel cell penetrating peptide as vector for therapeutic vaccine”
Time and place:
Friday 23/01-2015, 11.00-11.45
IKF, seminar room 2, 1st floor
Madiha Derouazi has been working on vector engineering and therapeutic cancer vaccines for over 10 years. She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research, the so called bench-to-bedside.
After several years working on recombinant protein production (upstream), she started developing different antigen delivery vectors. In the Laboratory of Tumor Immunology of the University of Geneva, she designed and characterized the cell penetrating peptide (CPP)-based multi-epitopic cancer vaccine that is currently being progressed by Amal Therapeutics.
Madiha Derouazi holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.
If you wish to discuss with Madiha, please contact Sébastien Wälchli (Sebastien.Walchli@rr-research.no)